Literature DB >> 8274108

Severe impairment battery. A neuropsychological test for severely demented patients.

M Panisset1, M Roudier, J Saxton, F Boller.   

Abstract

OBJECTIVE: Patients with progressive dementia invariably evolve to a stage where they can no longer be tested by standard neuropsychological tests. We studied the use of the Severe Impairment Battery (SIB) in such patients.
DESIGN: Case series.
SETTING: Geriatric long-term facility. PATIENTS: Sixty-nine patients who met the criteria of the Diagnostic and Statistical Manual for Mental Disorders, Revised Third Edition, for dementia were selected. The diagnosis of probable Alzheimer's disease was established according to the guidelines suggested by the National Institute of Neurologic and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association. There were 18 men and 51 women. The mean age of the population was 82.99 +/- 5.66 years. The mean Mini-Mental State Examination (MMSE) score was 10.71 +/- 6.14. MAIN OUTCOME MEASURE: To characterize the cognitive profile and evolution of severely demented patients by means of the SIB.
RESULTS: The mean score on the SIB was 92.52 +/- 31.92, with a possible maximum of 133 points. Subgroups of patients with the most severe degree of dementia (MMSE scores of 0 to 5 and 6 to 11) showed significant differences in their scores on the SIB. In contrast, no differences were found between subgroups with MMSE scores of 6 to 11, 12 to 17, and greater than 17. Fifteen patients who had MMSE scores of less than 6 had SIB scores ranging from 7 to 81. All cognitive domains showed a deterioration across the four severity groups as determined by the MMSE scores and also during a longitudinal study performed on 26 patients.
CONCLUSION: Our study indicates that the SIB is useful for the neuropsychological evaluation of severely demented patients and for their follow-up.

Entities:  

Mesh:

Year:  1994        PMID: 8274108     DOI: 10.1001/archneur.1994.00540130067012

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  64 in total

1.  Cognitive performance in centenarians and the oldest old: norms from the Georgia Centenarian Study.

Authors:  L Stephen Miller; Meghan B Mitchell; John L Woodard; Adam Davey; Peter Martin; Leonard W Poon; S M Jazwinski; R C Green; M Gearing; W R Markesbery; M A Johnson; J S Tenover; W L Rodgers; D B Hausman; J Arnold; I C Siegler
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2010-06-02

Review 2.  The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

Authors:  Jaclyn Cappell; Nathan Herrmann; Stephen Cornish; Krista L Lanctôt
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

3.  Rapid assessment of cognitive function in down syndrome across intellectual level and dementia status.

Authors:  D M Walsh; E Doran; W Silverman; A Tournay; N Movsesyan; I T Lott
Journal:  J Intellect Disabil Res       Date:  2015-05-29

Review 4.  A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.

Authors:  Jacob S Buckley; Shelley R Salpeter
Journal:  Drugs Aging       Date:  2015-06       Impact factor: 3.923

5.  Frontal white matter integrity in adults with Down syndrome with and without dementia.

Authors:  David Powell; Allison Caban-Holt; Gregory Jicha; William Robertson; Roberta Davis; Brian T Gold; Frederick A Schmitt; Elizabeth Head
Journal:  Neurobiol Aging       Date:  2014-02-04       Impact factor: 4.673

6.  Combining drug and music therapy in patients with moderate Alzheimer's disease: a randomized study.

Authors:  Anna Rita Giovagnoli; Valentina Manfredi; Letizia Schifano; Chiara Paterlini; Annalisa Parente; Fabrizio Tagliavini
Journal:  Neurol Sci       Date:  2018-03-17       Impact factor: 3.307

7.  Profiles of cognitive functioning in a population-based sample of centenarians using factor mixture analysis.

Authors:  Adam Davey; Ting Dai; John L Woodard; L Stephen Miller; Yasuyuki Gondo; Mary Ann Johnson; Dorothy B Hausman; Peter Martin; Robert C Green; Robert H Allen; Sally P Stabler; Leonard W Poon
Journal:  Exp Aging Res       Date:  2013       Impact factor: 1.645

8.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

9.  Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease.

Authors:  Umamon Puangthong; Ging-Yuek Robin Hsiung
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-02       Impact factor: 2.570

Review 10.  Treatment of Alzheimer's disease across the spectrum of severity.

Authors:  Shailaja Shah; William E Reichman
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.